Dual-mode imaging with radiolabeled gold nanorods

Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan 48109-5667, USA.
Journal of Biomedical Optics (Impact Factor: 2.86). 05/2011; 16(5):051307. DOI: 10.1117/1.3580277
Source: PubMed


Many nanoparticle contrast agents have difficulties with deep tissue and near-bone imaging due to limited penetration of visible photons in the body and mineralized tissues. We are looking into the possibility of mediating this problem while retaining the capabilities of the high spatial resolution associated with optical imaging. As such, the potential combination of emerging photoacoustic imaging and nuclear imaging in monitoring of antirheumatic drug delivery by using a newly developed dual-modality contrast agent is investigated. The contrast agent is composed of gold nanorods (GNRs) conjugated to the tumor necrosis factor (TNF-α) antibody and is subsequently radiolabeled by (125)I. ELISA experiments designed to test TNF-α binding are performed to prove the specificity and biological activity of the radiolabeled conjugated contrast agent. Photoacoustic and nuclear imaging are performed to visualize the distribution of GNRs in articular tissues of the rat tail joints in situ. Findings from the two imaging modalities correspond well with each other in all experiments. Our system can image GNRs down to a concentration of 10 pM in biological tissues and with a radioactive label of 5 μCi. This study demonstrates the potential of combining photoacoustic and nuclear imaging modalities through one targeted contrast agent for noninvasive monitoring of drug delivery as well as deep and mineralized tissue imaging.

Download full-text


Available from: Nicholas Kotov, Apr 07, 2014
  • Source
    • "ultrasound, SPECT, MRI) does not only potentially give rise to new multimodality systems with an augmented diagnostic capability beyond the inherent limitations of individual components, but also to multimodal contrast agents. Recent efforts for such integration have motivated photoacoustic researchers to develop so-called hybrid contrast agents, such as perfluorocarbon-capsulated gold nanoparticles as a dual contrast agent for photoacoustic and ultrasound modalities [10], radioisotope (125I)-labeled gold nanorod as a dual contrast agent for photoacoustic and nuclear imaging (SPECT) [11], and gold-coated iron oxide (Fe3O4) nanoparticles for a new magnetomotive photoacoustic (mmPA) imaging [26,27]. The latter technique (mmPA) applies an external magnetic field across gold-coated magnetic (iron oxide; magnetite Fe3O4) nanoparticles during the photoacoustic data acquisition time, thereby yielding magnetically-induced movement of the nanoparticles which separates them from the non-magnetic static background. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we report for the first time the use of silica-coated superparamagnetic iron oxide nanoparticles (SPION) as contrast agents in biomedical photoacoustic imaging. Using frequency-domain photoacoustic correlation (the photoacoustic radar), we investigated the effects of nanoparticle size, concentration and biological media (e.g. serum, sheep blood) on the photoacoustic response in turbid media. Maximum detection depth and the minimum measurable SPION concentration were determined experimentally. The nanoparticle-induced optical contrast ex vivo in dense muscular tissues (avian pectus and murine quadricept) was evaluated and the strong potential of silica-coated SPION as a possible photoacoustic contrast agents was demonstrated.
    Full-text · Article · Oct 2012 · Biomedical Optics Express
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Photoacoustic imaging is a biomedical imaging modality that provides functional information, and, with the help of exogenous contrast agents, cellular and molecular signatures of tissue. In this article, we review the biomedical applications of photoacoustic imaging assisted with exogenous contrast agents. Dyes, noble metal nanoparticles, and other constructs are contrast agents which absorb strongly in the near-infrared band of the optical spectrum and generate strong photoacoustic response. These contrast agents, which can be specifically targeted to molecules or cells, have been coupled with photoacoustic imaging for preclinical and clinical applications ranging from detection of cancer cells, sentinel lymph nodes, and micrometastasis to angiogenesis to characterization of atherosclerotic plaques. Multi-functional agents have also been developed, which can carry drugs or simultaneously provide contrast in multiple imaging modalities. Furthermore, contrast agents were used to guide and monitor the therapeutic procedures. Overall, photoacoustic imaging shows significant promise in its ability to assist in diagnosis, therapy planning, and monitoring of treatment outcome for cancer, cardiovascular disease, and other pathologies.
    Full-text · Article · Nov 2011 · Annals of Biomedical Engineering
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: For better examination of inflammation, we designed inflammation-targeted nuclear and optical dual-modality contrast agents prepared by I-125 radiolabeling of gold nanorods (GdNRs) conjugated with anti-intercellular adhesion molecule 1 (ICAM-1) antibody. The bioactivity and specific binding of the PEGylated (125)I-ICAM-GdNR conjugates to the ICAM-1 was validated through ELISA testing. Inflammation-targeted imaging was then conducted on an adjuvant-induced arthritic rat model which demonstrated an elevation of ICAM-1 level in the affected ankle joints. Facilitated by the I-125 radioisotope and the whole-body imaging via the Gamma camera, the time-dependent distribution of the systemically injected agent as well as the uptake of the agent in the inflammatory articular tissues could be examined conveniently and quantitatively. The success in targeted delivery of gold nanoparticles to inflammatory tissue enables both nuclear and optical imaging of inflammation at molecular or cellular level. Other than diagnosis, radiolabeled gold nanoparticles also hold promise for targeted therapy of a variety of disorders.
    Full-text · Article · Nov 2011 · ACS Nano
Show more